Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug40 | 25 post non-ICU patients Wiki | 1.00 |
drug269 | Appendectomy Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D000208 | Acute Disease NIH | 0.71 |
D001064 | Appendicitis NIH | 0.50 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
In this monocentric, prospective and descriptive trial we want to evaluate the long-term consequences for patients treated for Covid-19. Covid patients who were hospitalized for min. 5 days either in a Covid-19 department or in intensive care unit will be followed-up for 8 weeks after hospital discharge. This is done via an innovative electronic platform in the home environment (UZA@home). On the one hand the quality of life, rehabilitation and reintegration of the patient will be evaluated and on the other hand the patient will be screened for various psychosocial aspects such as anxiety, depression and post-traumatic stress syndrome.
Description: Evaluation of Quality of Life after hospitalization due to COVID-19 infection using the EQ-5D-5L questionnaire
Measure: Health related Quality of life (general well-being) questionnaire Time: week 0Description: Evaluation of Quality of Life after hospitalization due to COVID-19 infection using the EQ-5D-5L questionnaire
Measure: Health related Quality of life (general well-being) questionnaire Time: week 4Description: Evaluation of Quality of Life after hospitalization due to COVID-19 infection using the EQ-5D-5L questionnaire
Measure: Health related Quality of life (general well-being) questionnaire Time: week 8Description: Evaluation of revalidation of the patient after hospitalization (daily functioning and mobilization via a diary and objective measurements by means of remote monitoring techniques (saturation measurement, activity tracker, sleep monitor)).
Measure: Revalidation Time: week 0 up to week 8Description: Evaluation of reintegration of the patient after hospitalization (daily functioning and mobilization via a diary and objective measurements by means of remote monitoring techniques (saturation measurement, activity tracker, sleep monitor)).
Measure: Reintegration Time: week 0 up to week 8Description: Evaluation of depression and anxiety of the patient after hospitalization via the HADS (Hospital Anxiety and Depression Scale) questionnaire
Measure: Depression or anxiety Time: week 0Description: Evaluation of depression and anxiety of the patient after hospitalization via the HADS (Hospital Anxiety and Depression Scale) questionnaire
Measure: Depression or anxiety Time: week 4Description: Evaluation of depression and anxiety of the patient after hospitalization via the HADS (Hospital Anxiety and Depression Scale) questionnaire
Measure: Depression or anxiety Time: week 8Description: Evaluation of post traumatic stress syndrome of the patient after hospitalization via the PTSS questionnaire (of Erik De Soir)
Measure: Post traumatic stress syndrome Time: week 8Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports